Cepheid erhält FDA-Zulassung für Hämorrhagisches-Fieber-Test
Die FDA hat einen Hämorrhagisches-Fieber-Test von Cepheid, einer Tochter von Danaher, zugelassen.
Related stories
Polymarket Receives NFA Approval for PM Derivatives Futures Commission Merchant
PM Derivatives, LLC has received regulatory approval to act as a broker for customers on a fully collateralized basis.
M impact | REGULATION | Nov 03, 2026, 06:00 PM UTC
Cboe Joins Challenge to CFTC Approval of Single-Stock Perpetual Derivatives
Cboe Global Markets joined a Capital Markets Alliance challenge to CFTC approval of single-stock perpetual derivatives.
L impact | REGULATION | Nov 03, 2026, 05:38 PM UTC
Danaher’s Cepheid Wins FDA Clearance for Hemorrhagic Fever Test
Danaher’s Cepheid received FDA clearance for a hemorrhagic fever test.
M impact | REGULATION | Nov 03, 2026, 05:36 PM UTC
Cboe Joins Lawsuit Challenging CFTC Approval of Perpetual Stock Derivatives
Cboe has joined a lawsuit challenging the CFTC’s approval of perpetual derivatives tied to U.S. stocks and ETFs.
L impact | REGULATION | Nov 03, 2026, 05:35 PM UTC
Spain to Cut Train Frequencies and Strengthen Safety After Accident
Spain will reduce train frequencies and strengthen safety measures following an accident.
L impact | REGULATION | Nov 03, 2026, 05:35 PM UTC
Trump Says He Will Stop Sending Money to Israel
M impact | REGULATION | Nov 03, 2026, 05:24 PM UTC